Date:	2023/04/03
Your Name:	Natsuko Nozaki-Taguchi
Manuscript Title:	Continuous monitoring of activity and vital signs with load cells under the bed legs in
advanced cancer	patients, a prospective exploratory observational study. Can it represent performance status?
Manuscript numb	per (if known): APM-22-1235

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time mame. Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	

4	Consulting fees	X None	
7	Consulting rees		
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Command for additional to a	V. Nana	
7	Support for attending meetings and/or travel	XNone	
	, , , , , , , , , , , , , , , , , , ,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	<u></u>	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
13	financial interests	X_None	

This study used some data obtained during collaborative research between Chiba Oniversity and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/04/03
Your Name:	Hiromichi Takai
Manuscript Title:	Continuous monitoring of activity and vital signs with load cells under the bed legs in advanced
cancer patients,	a prospective exploratory observational study. Can it represent performance status?
Manuscript numl	per (if known): APM-22-1235

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	maricial interests		

This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/04/03
Your Name: _	Koyo Shono
Manuscript T	tle: Continuous monitoring of activity and vital signs with load cells under the bed legs in
advanced car	cer patients, a prospective exploratory observational study. Can it represent performance status?
Manuscript n	ımber (if known): APM-22-1235

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	

4 Consulting fees X None X None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None				
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Payment for expert X_None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None	_		V. Norse	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	ь		xNone	
Meetings and/or travel		testimony		
Meetings and/or travel	7	Support for attending	Y None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None X None X None X None	′		None	
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None		meetings and or traver		
pending Participation on a Data Safety Monitoring Board or Advisory Board Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical X None X None X None X None				
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None 12 Receipt of equipment, materials, drugs, medical	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None	9	Participation on a Data	X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical X_None	10	Leadership or fiduciary role	XNone	
group, paid or unpaid 11 Stock or stock options X_None Receipt of equipment, materials, drugs, medical X_None				
11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical X_None X_None X_None		-		
12 Receipt of equipment, materials, drugs, medicalX_None		group, paid or unpaid		
materials, drugs, medical	11	Stock or stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		X_None	
writing, gifts or other				
services		services		
13 Other financial or nonX_None	13		XNone	
financial interests		financial interests		

This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/04/03
Your Name:	Yuko Mizuno
Manuscript Title:	Continuous monitoring of activity and vital signs with load cells under the bed legs in advanced
cancer patients,	a prospective exploratory observational study. Can it represent performance status?
Manuscript numl	ber (if known): APM-22-1235

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the finda	plaining of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc.	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
c	educational events Payment for expert	X None	
6	testimony	xnone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and, or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

This study used data obtained during collaborative research between Chiba Lniversity and Minebeamitsumi knc.

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/04/03
Your Name:	Makoto Hasegawa
Manuscript Title:	Continuous monitoring of activity and vital signs with load cells under the bed legs in advanced
cancer patients,	a prospective exploratory observational study. Can it represent performance status?
Manuscript numb	per (if known): APM-22-1235

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4 Consulting fees X None X None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None				
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Payment for expert X_None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None	_		V. Norse	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	ь		xNone	
Meetings and/or travel		testimony		
Meetings and/or travel	7	Support for attending	Y None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None X None X None X None	′			
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None		meetings and or traver		
pending Participation on a Data Safety Monitoring Board or Advisory Board Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical X None X None X None X None				
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None 12 Receipt of equipment, materials, drugs, medical	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None	9	Participation on a Data	X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical X_None	10	Leadership or fiduciary role	XNone	
group, paid or unpaid 11 Stock or stock options X_None Receipt of equipment, materials, drugs, medical X_None				
11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical X_None X_None X_None		-		
12 Receipt of equipment, materials, drugs, medicalX_None		group, paid or unpaid		
materials, drugs, medical	11	Stock or stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		X_None	
writing, gifts or other				
services		services		
13 Other financial or nonX_None	13		XNone	
financial interests		financial interests		

This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date: April 4, 2023				
Your Name:	Yasunori sato			
Manuscript Tit	e: Continuous monitoring of activity and vital signs with load cells under the bed legs in advanced			
cancer patient	s, a prospective exploratory observational study. Can it represent performance status?			
Manuscript nui	mber (if known): APM-22-1235			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Minebeamitsumi Inc.	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4 Consulting fees X None X None				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	4	Consulting fees	XNone	
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None	5		XNone	
manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical				
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None				
Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Payment for expert X_None				
testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Receipt of equipment, materials, drugs, medical Z_None	_		V. Norse	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical	ь		xNone	
Meetings and/or travel		testimony		
Meetings and/or travel	7	Support for attending	Y None	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None X None X None X None X None	′		None	
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None		meetings and or traver		
pending Participation on a Data Safety Monitoring Board or Advisory Board Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical X None X None X None X None				
pending Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None X_None X_None				
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None X_None 12 Receipt of equipment, materials, drugs, medical	8	Patents planned, issued or	XNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None		pending		
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None	9	Participation on a Data	X None	
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None				
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical		Advisory Board		
committee or advocacy group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical X_None	10	Leadership or fiduciary role	XNone	
group, paid or unpaid 11 Stock or stock options X_None Receipt of equipment, materials, drugs, medical X_None				
11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical X_None X_None X_None		-		
12 Receipt of equipment, materials, drugs, medicalX_None		group, paid or unpaid		
materials, drugs, medical	11	Stock or stock options	XNone	
materials, drugs, medical				
materials, drugs, medical				
	12		X_None	
writing, gifts or other				
services		services		
13 Other financial or nonX_None	13		XNone	
financial interests		financial interests		

This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:

Date:	April 4, 2023			•
Your Name:	Shiroh Isono			•
Manuscript Title:	Continuous monitoring of	activity and vital signs	with load cells under t	he bed legs in
advanced cancer pat	ients, a prospective exploratory	observational study.	Can it represent perfo	rmance status?
Manuscript number (if known): APM-22-1235				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
All support for the present manuscript (e.g., funding,	Daiichi-Sankyo research fund A22-1073	Fund payments made to our institution. Primary investigator.
provision of study materials, medical writing, article processing charges, etc.)	Minebeamitsumi Inc.	This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.
No time limit for this item.		
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above)	Minebeamitsumi Inc.	Grants for the industry-Academia Joint Research
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Time frame: past Grants or contracts from any entity (if not indicated

3	Royalties or licenses	Minebeamitsumi Inc.	S.I is one of inventors of the device used in this study and received royalties from the Minebeamitsumi Inc.
4	Consulting fees	AMCA	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	Minebeamitsumi Inc.	S.I. is one of inventors for the issued or pending patents of the devise used in this study.
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

SI as a head of the Department of Anesthesiology, Chiba University, is one of the inventors of the vital sign monitoring system used in this study and received royalties and grants for the industry-Academia Joint Research from Minebeamitsumi Inc. SI is also one of the inventors for the issued or pending patents of the devise used in this study. SI received research funding from Daiichi-Sankyo, A22-1073 which will be used as an article processing charge. This study used data obtained during collaborative research between Chiba University and Minebeamitsumi Inc.

Please place an "X" next to the following statement to indicate your agreement:X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.